City of Hope

128 articles about City of Hope

• City of Hope researchers identify biomarkers that may detect risk of advance prostate cancer in Black men

  8/15/2023

  Scientists at City of Hope, one of the largest cancer research and treatment organizations in the United States and a leading research center for diabetes and other life-threatening illnesses, have identified a cell metabolism process found in men with diabetes and metastatic prostate cancer that could one day lead to improved testing and treatments for Black men with these diseases.

• City of Hope receives $32.3 million from the California Institute for Regenerative Medicine to advance innovative therapies for patients

  8/9/2023

  Researchers at City of Hope were awarded $32.3 million from the California Institute for Regenerative Medicine to support three novel Phase 1 clinical trials evaluating innovative cell and gene therapy treatments for patients with HIV, acute myeloid leukemia and severe aplastic anemia.

• City of Hope scientists develop targeted chemotherapy able to kill all solid tumors in preclinical research

  8/1/2023

  Researchers at City of Hope today published a new study explaining how they took a protein once thought to be too challenging for targeted therapy, proliferating cell nuclear antigen (PCNA), and developed a targeted chemotherapy that appears to annihilate all solid tumors in preclinical research.

• Calidi Biotherapeutics and City of Hope Announce First Patient Dosed in a Phase 1 Clinical Trial Evaluating Neural Stem Cells Engineered to Carry an Oncolytic Virus, CLD-101, in Recurrent High-grade Glioma Patients

  7/18/2023

  City of Hope, one of the largest cancer research and treatment organizations in the United States and a National Cancer Institute-designated comprehensive cancer Center, and Calidi Biotherapeutics Inc. today jointly announced that the first brain tumor patient was treated at City of Hope.

• City of Hope's Spirit of Life Celebration Gala Delivers Unforgettable Evening for Dr. Farouk Shami

  7/14/2023

  The City of Hope's highly anticipated Spirit of Life Celebration gala honoring Dr. Farouk Shami, chairman and founder of Farouk Systems, Inc., invited hundreds of esteemed beauty industry leaders to an enchanting evening of philanthropy, entertainment, and inspiration.

• Race executes global license agreement with City of Hope to access FTO IP

  7/10/2023

  Race executes worldwide license agreement with City of Hope, one of the largest cancer research and treatment organisations in the United States.

• City of Hope appoints David W. Craig, Ph.D., as founding chair of its new Department of Integrative Translational Sciences within its Beckman Research Institute

  6/29/2023

  City of Hope announced that effective June 30, David W. Craig, Ph.D., will be professor and founding chair of its newly created Department of Integrative Translational Sciences within Beckman Research Institute of City of Hope.

• City of Hope diabetes experts present new research on beta cells, insulin secretion and islet transplantation at annual American Diabetes Association (ADA) Conference

  6/27/2023

  City of Hope, one of the largest cancer research and treatment organizations in the United States and a leading research center for diabetes and other life-threatening illnesses, presented novel research that seeks to better understand what causes type 1 and type 2 diabetes and how to improve its treatment at the 83rd Scientific Sessions of ADA held June 23 to 26 in San Diego.

• Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program

  6/15/2023

  Helocyte, Inc., a subsidiary company of Fortress Biotech, Inc., announced that the National Cancer Institute has awarded a $3.22 million grant to City of Hope for clinical studies of Triplex, a cytomegalovirus vaccine being developed by Helocyte and City of Hope.

• Ostentus Therapeutics, Inc., and City of Hope to Continue Studies of Novel OST Natural Products for Treatment of Leukemia and Other Cancers

  5/31/2023

  Ostentus Therapeutics, Inc., announced that it has entered into a second Sponsored Research Agreement with City of Hope, one of the largest cancer research and treatment organizations in the United States, to conduct preclinical research on OST compounds, which could be used as future therapies for leukemia and other cancers.

• City of Hope researchers will present new treatments for blood, prostate and other cancers at 2023 American Society of Clinical Oncology Annual Meeting

  5/26/2023

  City of Hope announced it would present research on promising treatments for blood, prostate and other cancers, as well as studies on germline testing for hereditary cancers and on reducing heart disease in childhood cancer survivors, at the 2023 American Society of Clinical Oncology's annual conference from June 2 to 6 in Chicago.

• City of Hope presents new research on cancer immunotherapies at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

  5/22/2023

  City of Hope announced that one of its researchers will present results from a SWOG Cancer Research Network Phase 3 study comparing nivolumab and brentuximab vedotin in patients with advanced stage classic Hodgkin lymphoma at an ASCO press briefing.

• City of Hope Honored Among 'Top Hospitals and Health Systems' for Diversity, Equity and Inclusion

  5/3/2023

  City of Hope, one of the largest cancer research and treatment organizations in the United States, has been recognized by DiversityInc as one of the nation's "Top Hospitals and Health Systems" for diversity, equity and inclusion.

• Chandana Lall, M.D., M.B.A., to join City of Hope as chair of diagnostic radiology and vice dean of clinical faculty affairs

  4/28/2023

  City of Hope, one of the largest cancer research and treatment organizations in the United States, has announced Chandana "Sandy" Lall, M.D., M.B.A., will join the organization as chair of Diagnostic Radiology and vice dean of clinical faculty affairs, effective July 1, 2023.

• City of Hope scientists present potential new treatments for chronic lymphocytic leukemia, myelofibrosis and other diseases at American Association of Cancer Research (AACR) Annual Meeting

  4/17/2023

  City of Hope will showcase breakthrough research and innovative studies at this year's American Association for Cancer Research (AACR) Annual Meeting, which takes place April 14 to 19 in Orlando, Florida.

• Andrew T. Leitner, M.D., appointed chair of City of Hope Department of Supportive Care Medicine

  4/17/2023

  City of Hope, one of the largest cancer research and treatment organizations in the United States and a national leader in providing cancer patients with best-in-class, integrated supportive care programs, announced that Andrew T. Leitner, M.D., has been appointed chair of the Department of Supportive Care Medicine and Arthur M. Coppola Family Chair in Supportive Care Medicine.

• City of Hope appoints John D. Carpten, Ph.D., as director of its comprehensive cancer center and Beckman Research Institute, and chief scientific officer

  4/6/2023

  City of Hope today announced the appointment of John D. Carpten, Ph.D., as director of the National Cancer Institute-designated comprehensive cancer center, director of Beckman Research Institute of City of Hope and chief scientific officer.

• City of Hope Comprehensive Cancer Center earns highest ranking from National Cancer Institute

  2/16/2023

  City of Hope announced that its comprehensive cancer center has received the highest rating possible for a U.S. cancer center — "exceptional" — by the National Cancer Institute, the federal government's principal agency for cancer research and training.

• City of Hope to Rebrand Cancer Treatment Centers of America Locations to Reflect Transition to National System

  2/1/2023

  City of Hope, one of the largest cancer research and treatment organizations in the United States, announced that its subsidiary, Cancer Treatment Centers of America®, will fully transition its clinical locations to City of Hope's brand.

• Nautilus Biotechnology Partners with the Translational Genomics Research Institute (TGen) to Investigate Applications of Single-Molecule Proteomic Analysis in Diffuse Intrinsic Pontine Glioma (DIPG)

  1/19/2023

  Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform, and the Translational Genomics Research Institute, part of City of Hope, announced a partnership to explore the utility of the Nautilus platform by studying specific protein targets in diffuse intrinsic pontine glioma, a rare and often fatal childhood cancer.